Biologic therapy in Crohn's disease: Review of the evidence

Research output: Contribution to journalReview article

10 Citations (Scopus)

Abstract

It is expected that within a few months, there will be commercially available in the United States a total of 3 biologic agents with inhibition of tumor necrosis factor-α. (TNF-α) as the primary mechanism of action: infliximab, adalimumab, and certolizumab pegol. The primary efficacy data for each of these agents are reviewed. All 3 agents appear to be efficacious for both induction and maintenance of remission in Crohn's disease. There are no trials comparing these agents, but one can infer from available data that they have broadly similar efficacy. Adverse events associated with anti-TNF-α therapy, including infection, infusion reactions, autoimmunity, risk of malignancy, and neurologic events, are reviewed.

Original languageEnglish (US)
JournalReviews in Gastroenterological Disorders
Volume7
Issue numberSUPPL. 1
StatePublished - 2007

Fingerprint

Remission Induction
Biological Therapy
Biological Factors
Autoimmunity
Crohn Disease
Nervous System
Tumor Necrosis Factor-alpha
Maintenance
Infection
Neoplasms
Therapeutics
Certolizumab Pegol
Infliximab
Adalimumab

Keywords

  • Adalimumab
  • Certolizumab pegol
  • Crohn's disease
  • Infliximab
  • TNF-α

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Biologic therapy in Crohn's disease : Review of the evidence. / Loftus, Jr, Edward Vincent.

In: Reviews in Gastroenterological Disorders, Vol. 7, No. SUPPL. 1, 2007.

Research output: Contribution to journalReview article

@article{6e95acb1775d4af2a8efd1cd8f477928,
title = "Biologic therapy in Crohn's disease: Review of the evidence",
abstract = "It is expected that within a few months, there will be commercially available in the United States a total of 3 biologic agents with inhibition of tumor necrosis factor-α. (TNF-α) as the primary mechanism of action: infliximab, adalimumab, and certolizumab pegol. The primary efficacy data for each of these agents are reviewed. All 3 agents appear to be efficacious for both induction and maintenance of remission in Crohn's disease. There are no trials comparing these agents, but one can infer from available data that they have broadly similar efficacy. Adverse events associated with anti-TNF-α therapy, including infection, infusion reactions, autoimmunity, risk of malignancy, and neurologic events, are reviewed.",
keywords = "Adalimumab, Certolizumab pegol, Crohn's disease, Infliximab, TNF-α",
author = "{Loftus, Jr}, {Edward Vincent}",
year = "2007",
language = "English (US)",
volume = "7",
journal = "Reviews in Gastroenterological Disorders",
issn = "1533-001X",
publisher = "MedReviews LLC",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Biologic therapy in Crohn's disease

T2 - Review of the evidence

AU - Loftus, Jr, Edward Vincent

PY - 2007

Y1 - 2007

N2 - It is expected that within a few months, there will be commercially available in the United States a total of 3 biologic agents with inhibition of tumor necrosis factor-α. (TNF-α) as the primary mechanism of action: infliximab, adalimumab, and certolizumab pegol. The primary efficacy data for each of these agents are reviewed. All 3 agents appear to be efficacious for both induction and maintenance of remission in Crohn's disease. There are no trials comparing these agents, but one can infer from available data that they have broadly similar efficacy. Adverse events associated with anti-TNF-α therapy, including infection, infusion reactions, autoimmunity, risk of malignancy, and neurologic events, are reviewed.

AB - It is expected that within a few months, there will be commercially available in the United States a total of 3 biologic agents with inhibition of tumor necrosis factor-α. (TNF-α) as the primary mechanism of action: infliximab, adalimumab, and certolizumab pegol. The primary efficacy data for each of these agents are reviewed. All 3 agents appear to be efficacious for both induction and maintenance of remission in Crohn's disease. There are no trials comparing these agents, but one can infer from available data that they have broadly similar efficacy. Adverse events associated with anti-TNF-α therapy, including infection, infusion reactions, autoimmunity, risk of malignancy, and neurologic events, are reviewed.

KW - Adalimumab

KW - Certolizumab pegol

KW - Crohn's disease

KW - Infliximab

KW - TNF-α

UR - http://www.scopus.com/inward/record.url?scp=33847606974&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33847606974&partnerID=8YFLogxK

M3 - Review article

C2 - 17392631

AN - SCOPUS:33847606974

VL - 7

JO - Reviews in Gastroenterological Disorders

JF - Reviews in Gastroenterological Disorders

SN - 1533-001X

IS - SUPPL. 1

ER -